News >

Developments With Gastrointestinal NETs Continue to Grow

Danielle Bucco
Published: Friday, Jan 05, 2018

Diane Reidy-Lagunes, MD

Diane Reidy-Lagunes, MD
2017 was an important year for patients with neuroendocrine tumors (NETs). Diane Reidy-Lagunes, MD, said the phase III NETTER-1 trial comparing Lutathera (lutetium [177Lu] oxodotreotide) plus best supportive care versus octreotide (Sandostatin) LAR was a significant development in the treatment of patients with advanced midgut NETs.

on Gastrointestinal Cancers, Reidy-Lagunes, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed ongoing developments for the treatment of patients with gastrointestinal (GI) and pancreatic NETs.

OncLive: Please provide an overview of your presentation on GI and pancreatic NETs.

Reidy-Lagunes: I gave an overview on the treatment of NETs, which is changing quickly, but also how you diagnose and define the patient and develop personalized medicine. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Navigating Treatment Decisions in mCRC: Sequencing Through Multiple Lines of CareMar 26, 20201.5
Community Practice Connections™: Optimizing Care in the Era of an Expanding Armamentarium for Hepatocellular CarcinomaMar 29, 20202.0
Publication Bottom Border
Border Publication